Positive Phase III Clinical Results for EirGenix's Proposed Tr...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TAIPEI, March 23, 2021 /PRNewswire-AsiaNet/ -- In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary ...
Authors: LATEST ASIANET NEWS RELEASES